Alzheimer’s researchers David M. Holtzman, MD, and Celeste Karch, PhD, at the School of Medicine, have been recognized by the Rainwater Charitable Foundation for scientific achievements that could lead to new, effective treatments for neurodegenerative diseases associated with the accumulation of tau protein in the brain. Alzheimer’s is the best known such disease.
A new study from Washington University School of Medicine in St. Louis has uncovered a previously unknown role for exosomes in inflammatory respiratory diseases. The study has implications for finding new therapies.
Pathologist Richard J. Cote, MD, the Edward Mallinckrodt Professor at the School of Medicine, has been elected a senior member of the National Academy of Inventors.
WashU alumni are among the researchers working around-the-clock on the Pfizer-BioNTech vaccine. They say they won’t rest until there are no more deaths from COVID-19.
Roger Smith, AB ’93, MS ’96 wanted to help others who had hearing loss like him. So he joined the company that gave him sound back.
Applications are now being accepted for the Specialized Programs of Research Excellence (SPORE) in Leukemia Career Enhancement Program and the Developmental Research Program, under principal investigator Daniel Link, MD, at the School of Medicine. Those interested should apply by April 30.
Samantha Kirstin Barrick, a postdoctoral scholar in biochemistry and molecular biophysics and in the laboratory of Michael J. Greenberg at the School of Medicine, received a three-year $208,182 fellowship award from the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH).
Researchers at Washington University School of Medicine and the University of Minnesota Medical School are leading a large, multicenter study to find out whether maintaining platelets in cold storage is as effective in reducing blood loss as platelets stored at room temperature.
Researchers at the School of Medicine have identified an antibody that, in mice, removes amyloid plaques from brain tissue and blood vessels without increasing the risk of brain bleeds.
Researchers at the School of Medicine have discovered that the ability to interact with other elements of the immune system is an indispensable part of the effectiveness of monoclonal antibodies. The findings could help improve the design of the next generation of COVID-19 drugs.